Agilent Technologies Inc. and Stemina Biomarker Discovery Announce Efforts to Accelerate Stem Cell Metabolite Biomarker Discovery

SANTA CLARA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina’s metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.

MORE ON THIS TOPIC